Tandem Diabetes Care Announces Third Quarter 2026 Financial Results

TANDEM DIABETES CARE INC (TNDM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces Third Quarter 2026 Financial Results San Diego, November 5, 2026 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM)

Event · Earnings
Also in this documentGuidance · reaffirm · $1.07B–$1.09B

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 5, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TNDM
Bullish
high confidence
Mentioned
$TNDM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TNDMBullishMed
01

Why it matters

The company showed solid top‑line growth, margin expansion, and a narrowed loss, reinforcing its growth narrative.

02

Market read

Earnings and guidance reaffirmation are the primary catalysts for TNDM, with modest upside potential for investors.

03

What to watch

Potential headwinds from reimbursement policy changes and competitive pressure from Abbott's Libre ecosystem.

Relevance 7/10Novelty 7/10Timing: today
AlphAI · Earnings readTNDM · Third Quarter 2026 · ended September 30, 2026

Tandem Diabetes Care Announces Third Quarter 2026 Financial Results

✓Solid quarter

Worldwide sales increased 14% to $283.7 million, gross margin rose to 57%, operating loss narrowed to $2.4 million, and adjusted EBITDA increased to $18.0 million. The company reaffirmed its 2026 sales, gross-margin and adjusted EBITDA-margin outlook.

United States pump sales, three months ended September 30
$83.4M
(2)% y/y
Gross margin · GAAP
57%
up 270 basis points y/y
EPS · GAAP
$(0.10)
Year ending December 31, 2026 outlook
Sales are estimated to be approximately $1.065 billion to $1.085 billion
GM approximately 56% to 57% of sales

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Sales, three months ended September 30GAAP$283.7M–14%
Cost of sales, three months ended September 30GAAP123,268––
Gross profit, three months ended September 30GAAP$160.4M––
Gross margin, three months ended September 30GAAP57%–up 270 basis points
Selling, general and administrative expense, three months ended September 30GAAP113,945––
Research and development expense, three months ended September 30GAAP48,846––
Total operating expenses, three months ended September 30GAAP162,791––
Operating loss, three months ended September 30GAAP−$2.37M––
GAAP operating margin, three months ended September 30GAAP(1)%–improved 830 basis points
Total other income (expense), net, three months ended September 30GAAP−$5.32M––
Loss before income taxes, three months ended September 30GAAP−$7.69M––
Income tax expense (benefit), three months ended September 30GAAP−$608K––
Net loss, three months ended September 30GAAP−$7.08M––
Net loss per share, basic and diluted, three months ended September 30GAAP$(0.10)––
Weighted average shares used to compute basic and diluted net loss per share, three months ended September 30GAAP69,650––
Adjusted EBITDA, three months ended September 30non-GAAP$18.04M––
Adjusted EBITDA margin, three months ended September 30non-GAAP6 %––
GAAP cash used in operating activities, three months ended September 30GAAP−$819K––
Capital expenditures, three months ended September 30other−$4.69M––
Free cash flow, three months ended September 30non-GAAP−$5.51M––
Sales, nine months ended September 30GAAP$785.5M–8%
Gross profit, nine months ended September 30GAAP$442.0M––
Operating loss, nine months ended September 30GAAP−$33.59M––
Net loss, nine months ended September 30GAAP−$48.65M––
Net loss per share, basic and diluted, nine months ended September 30GAAP$(0.70)––
Adjusted EBITDA, nine months ended September 30non-GAAP$27.18M––
Adjusted EBITDA margin, nine months ended September 30non-GAAP3 %––
GAAP cash used in operating activities, nine months ended September 30GAAP−$24.39M––
Free cash flow, nine months ended September 30non-GAAP−$39.4M––

Segments

SegmentRevenueq/qy/y
United States pump sales, three months ended September 30Pump sales$83.38M–(2)%
United States supplies and other sales, three months ended September 30Supplies and other sales$107.7M–19%
Total Sales in the United States, three months ended September 30U.S. shipments were nearly 23,000 pumps, compared to more than 20,000 pumps.$191.0M–9%
International pump sales, three months ended September 30Pump sales$31.57M–25%
International supplies and other sales, three months ended September 30Supplies and other sales$61.07M–26%
Total International Sales, three months ended September 30International shipments were nearly 11,000 pumps, compared to more than 9,000 pumps. International sales increased 27% in constant currency.$92.64M–26%
United States pump sales, nine months ended September 30Pump sales$244.3M–1%
United States supplies and other sales, nine months ended September 30Supplies and other sales$286.9M–13%
Total Sales in the United States, nine months ended September 30Sales by geography$531.2M–7%
International pump sales, nine months ended September 30Pump sales$95.71M–17%
International supplies and other sales, nine months ended September 30Supplies and other sales$158.6M–8%
Total International Sales, nine months ended September 30International sales increased 9% in constant currency.$254.3M–12%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Year ending December 31, 2026 outlook

  • RevenueSales are estimated to be approximately $1.065 billion to $1.085 billion
  • Gross marginapproximately 56% to 57% of sales
  • NoteU.S. sales of approximately $730 million to $745 million
  • NoteInternational sales of approximately $335 million to $340 million
  • NoteAdjusted EBITDA margin is estimated to be approximately 5% to 6% of sales
  • NoteNon-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $85 million.
  • NoteApproximately $65 million non-cash, stock-based compensation expense
  • NoteApproximately $20 million depreciation and amortization expense

What drove it

  • Worldwide sales increased 14% to $283.7 million.
  • International sales increased 26% to $92.6 million and increased 27% in constant currency.
  • U.S. supplies and other sales increased 19% to $107,664.
  • International supplies and other sales increased 26% to $61,070.
  • Gross margin was 57%, compared to 54%.
  • The pay-as-you-go reimbursement model resulted in 15% of U.S. sales through the pharmacy channel.
  • Pharmacy formulary coverage increased to approximately 50% of U.S. lives.
  • The company expanded t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus Sensor to 11 international markets and announced international availability of Tandem Mobi in 12 countries.

Concerns

  • U.S. pump sales were $83,381, compared to $84,785, a decline of (2)%.
  • The company reported a GAAP net loss of $(7,085) and a GAAP operating loss of $(2,369) for the third quarter.
  • Third-quarter GAAP cash used in operating activities was $(819), and non-GAAP free cash flow was $(5,506).
  • Nine-month non-GAAP free cash flow was $(39,400).
  • Convertible senior notes, net - long-term were $603,388 as of September 30, 2026.

What to watch

  • Execution against full-year sales guidance of approximately $1.065 billion to $1.085 billion.
  • U.S. sales guidance of approximately $730 million to $745 million and international sales guidance of approximately $335 million to $340 million.
  • Full-year gross-margin guidance of approximately 56% to 57% of sales.
  • Full-year adjusted EBITDA-margin guidance of approximately 5% to 6% of sales.
  • Adoption of the pay-as-you-go reimbursement model and pricing and transition assumptions for the U.S. pharmacy channel.
  • Expansion of international direct operations and availability of Tandem Mobi in 12 countries.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were $443,082 as of September 30, 2026, compared to $292,666 as of December 31, 2025.
  • Convertible senior notes, net - long-term were $603,388 as of September 30, 2026, compared to $310,036 as of December 31, 2025.
  • Total assets were $1,159,494 as of September 30, 2026, compared to $881,112 as of December 31, 2025.
  • Total liabilities were $1,024,407 as of September 30, 2026, compared to $725,942 as of December 31, 2025.
  • Total stockholders' equity was $135,087 as of September 30, 2026, compared to $155,170 as of December 31, 2025.
  • Nine-month GAAP cash used in operating activities was $(24,395), compared to $(19,510).
  • Nine-month capital expenditures were $(15,005), compared to $(13,263).
  • Nine-month non-GAAP free cash flow was $(39,400), compared to $(32,773).

Analysis

Tandem reported third-quarter worldwide sales of $283.7 million, up 14% from $249.3 million. U.S. sales increased 9% to $191.0 million, while international sales increased 26% to $92.6 million and 27% in constant currency. The geographic mix favored international growth, while U.S. supplies and other sales increased 19% and U.S. pump sales declined (2)% to $83,381.

Management, verbatim

Tandem’s third-quarter performance demonstrates that our strategy is delivering results. We are expanding access to Tandem’s life-changing technology, strengthening our business model, advancing our pipeline and driving greater operating efficiency, creating a stronger foundation for sustainable, profitable growth.

John Sheridan, president and chief executive officer

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported financial metrics
  • Non-GAAP earnings or loss per share
  • GAAP or non-GAAP tax-rate guidance
  • Operating-expense guidance
  • Share repurchases
  • Dividend declaration or payment
  • Prior financial guidance for comparison
  • CFO commentary

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Tandem Diabetes Care (Nasdaq: TNDM) released its Q3 2026 earnings via an SEC Form 8‑K, providing detailed financials and reaffirming its 2026 outlook.

Company-level read

Ticker impact

$TNDMBullishHigh confidence
Context

Tandem Diabetes Care reported Q3 2026 results and reaffirmed full-year guidance, showing higher sales, improved margins and a narrowed operating loss.

Expected impact

likely modest upside as investors price in stronger sales and margin improvement, but limited upside since guidance is only reaffirmed.

Evidence & confidence

Improved sales (+14% YoY), higher gross margin (+270 bps) and a much smaller operating loss signal operational progress; reaffirmed guidance reduces surprise risk.

Market effects

Positive for the diabetes device sector as Tandem's growth may boost peer valuations.

U.S. healthcare investors may see modest buying pressure.

Limited; primarily impacts U.S. med‑tech investors.

Counterpoint

If the reaffirmed guidance falls short of analyst expectations, the stock could face pressure despite the earnings beat.

Key entities

  • John Sheridan

    President and CEO who commented on the results.

Every TNDM earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.

$TNDMMed

Why is Tandem Diabetes Care stock rallying today?

Tandem Diabetes Care (TNDM) stock rose 6.3% in pre-market trading after Stifel upgraded it to Buy with a $26 price target, citing an improving product pipeline and compelling valuation. The firm expects 50% upside and positive developments over the next year. TNDM recently received FDA clearance for its Tobi platform and reported strong Q3 2026 earnings, with revenue of $283.7 million, exceeding estimates. The stock trades below its 52-week high of $29.65.

$TNDMMedAI 8/10

Expanded Insulin Delivery Systems

Tandem Diabetes Care received Health Canada approval for its t:x2 insulin pump, expanding eligibility to adults with type 2 diabetes and pregnant individuals with type 1 diabetes. The pump is compatible with Abbott's FreeStyle Libre 3 Plus sensor, enabling minute-by-minute glucose readings. Clinical trials showed improved glucose management, including additional time in target range during pregnancy.